Publication:
Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation

dc.contributor.authorAleka, Yetemwork
dc.contributor.authorIbarra-Meneses, Ana Victoria
dc.contributor.authorWorkineh, Meseret
dc.contributor.authorTajebe, Fitsumbrhan
dc.contributor.authorKiflie, Amare
dc.contributor.authorTessema, Mekibib Kassa
dc.contributor.authorMelkamu, Roma
dc.contributor.authorTadesse, Azeb
dc.contributor.authorMoreno, Javier
dc.contributor.authorvan Griensven, Johan
dc.contributor.authorCarrillo, Eugenia
dc.contributor.authorAdriaensen, Wim
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.date.accessioned2020-09-29T09:02:21Z
dc.date.available2020-09-29T09:02:21Z
dc.date.issued2020
dc.description.abstractVisceral leishmaniasis (VL) is a lethal disease if left untreated. Current treatments produce variable rates of treatment failure and toxicity without sterile cure, rendering treatment efficacy monitoring essential. To avoid repeated invasive tissue aspirates as well as empirical treatment, there is a need for new tools that allow a less-invasive and early assessment of treatment efficacy in the field. Cross-sectional studies have suggested levels of cytokines/chemokines after whole blood stimulation as good markers of cure, but longitudinal studies are lacking. In this study, we followed 13 active VL cases in an endemic area in Ethiopia by measuring the production of IFN-γ, TNF-α, IP-10, IL-2, IL-10, MCP-1, and MIG before, during, and at the end of treatment. After 24 hours of stimulation of whole blood with soluble Leishmania antigen, we observed an early, robust, and incremental increase of IFN-γ, TNF-α, and IP-10 levels in all patients during treatment. Moreover, based on the IFN-γ levels that showed an average 13-fold increase from the time of diagnosis until the end of treatment, we could almost perfectly discriminate active from cured status. Similar concentrations and patterns were found in stimulation assays with the two main Leishmania species. The levels of IFN-γ, IP-10, or TNF-α also seemed to be inversely associated with the parasite load at baseline. Despite a 1/10 drop in concentrations, similar patterns were observed in IFN-γ and IP-10 levels when dried plasma spots were stored at 4°C for an average of 225 days. All the above evidence suggests a detectable restoration of cell-mediated immunity in VL and its association with parasite clearance. With a potential application in rural settings by means of dried plasma spots, we recommend to further explore the early diagnostic value of such assays for treatment efficacy monitoring in large cohort studies including treatment failure cases.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipFunding was provided by the Belgian Directorate-General for Development Cooperation under the ITM-DGDC framework agreement FA-IIII. WA is personally supported by a Research Foundation Flanders postdoctoral fellowship. In addition, this work was funded by the Instituto de Salud Carlos III via the project PI18CIII/00029 and via the Red de Enfermedades Tropicales, Subprograma RETICS del Plan Estatal de I+D+I 2013-2016, which is cofunded by FEDER “Una manera de hacer Europa” funds, via projects RD16/0027/0017 and RD16CIII/0003/0002.es_ES
dc.format.page8385672es_ES
dc.format.volume2020es_ES
dc.identifier.citationJ Immunol Res 2020 Jan 23;2020:8385672.es_ES
dc.identifier.doi10.1155/2020/8385672es_ES
dc.identifier.e-issn2314-7156es_ES
dc.identifier.journalJournal of immunology researches_ES
dc.identifier.pubmedID32377538es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11080
dc.language.isoenges_ES
dc.publisherHindawies_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI18CIII/00029es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16/0027/0017es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0003/0002es_ES
dc.relation.publisherversionhttps://doi.org/10.1155/2020/8385672es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleWhole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluationes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationcf71e409-5422-4199-9853-f56c0cdc3e79
relation.isAuthorOfPublication831dbac1-fcb6-444a-90e1-4b562eecb934
relation.isAuthorOfPublicationbb8f1dfe-8a72-4881-a19f-0b83b988f1bb
relation.isAuthorOfPublication.latestForDiscoverycf71e409-5422-4199-9853-f56c0cdc3e79
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
WholeBloodStimulationAssay_2020.pdf
Size:
875.17 KB
Format:
Adobe Portable Document Format
Description:
Loading...
Thumbnail Image
Name:
Supplementary Material WholeBloodStimulationAssay_2020..pdf
Size:
92.41 KB
Format:
Adobe Portable Document Format
Description:
Material Suplementario